Report
EUR 14.08 For Business Accounts Only

OMNICELL increases its risk exposure and slightly lowers to Neutral

OMNICELL (US), a company active in the Medical Equipment industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date February 23, 2021, the closing price was USD 130.05 and its expected value was estimated at USD 123.67.
Underlying
Omnicell Inc.

Omnicel is a provider of medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions. The company manages its business as two operating segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software and services. The Medication Adherence segment primarily includes the development, manufacturing and selling of solutions to assist patients in becoming and remaining adherent to their medication regimens.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch